Bicara Therapeutics to Host Webinar to Review Latest Clinical Trial Data for BCA101
Webinar to be held Monday, September 12, 2022 at 10:30 a.m. ET
CAMBRIDGE, Mass., September 8, 2022 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent and durable immune response in the tumor microenvironment, today announced that it will host a virtual webinar to review the latest clinical trial data for BCA101, a first-in-class EGFR/TGFβ-trap bifunctional antibody designed to deliver superior anti-tumor efficacy with an improved therapeutic window to solid tumors. The webinar will be held Monday, September 12, 2022 at 10:30 a.m. ET.
During the webinar, Dr. Glenn Hanna, principal investigator from Dana-Farber Cancer Institute, will review the Phase 1 data presented at the European Society of Medical Oncology (ESMO) Congress 2022. Management will then discuss the development program in more detail, followed by a Q&A session. Presenters for the event are:
- Claire Mazumdar, Ph.D., Chief Executive Officer, Bicara Therapeutics
- Glenn J. Hanna, M.D., Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute and Principal Investigator in the Phase 1 trial for BCA101
- Liviu Niculescu, M.D., Chief Medical Officer, Bicara Therapeutics
BCA101 is a first-in-class EGFR / TGF-β-trap bifunctional antibody designed to enhance both innate and adaptive immune responses directly at the site of the tumor by binding to the well-validated EGFR antigen and disabling TGF-β, a signaling molecule that plays a key role in suppressing the immune response in the tumor microenvironment. Promising preclinical data suggest that BCA101 is superior to the anti-EGFR antibody cetuximab in preventing tumor recurrence, as well as in restoring immune activation. An ongoing Phase 1/1b clinical trial of BCA101, initiated in July 2020, has enrolled cohorts of patients in a dose-escalation study with BCA101 as a single agent, as well as in combination with pembrolizumab, a PD-1 inhibitor and a recommended dose for expansion has been declared. Enrollment in the dose expansion arm of the study in first-line head and neck in combination with pembrolizumab is currently ongoing. For more information, please visit study number NCT04429542 at www.clinicaltrials.gov.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Bicara’s lead asset, BCA101, a first-in-class EGFR / TGF-β-trap bifunctional antibody, is currently enrolling patients in a Phase 1/1b study. Bicara’s experienced team brings deep expertise across immunology, oncology, clinical development, business development and operational strategy.
Stern Investor Relations, Inc.
Ten Bridge Communications